Suppr超能文献

鉴定 C-6 为连接到微管稳定剂塔卡醇内酯的新连接点。

Identification of C-6 as a New Site for Linker Conjugation to the Taccalonolide Microtubule Stabilizers.

出版信息

J Nat Prod. 2019 Mar 22;82(3):583-588. doi: 10.1021/acs.jnatprod.8b01036. Epub 2019 Feb 25.

Abstract

The taccalonolides are a class of microtubule stabilizers that circumvent clinically relevant forms of drug resistance due to their unique mechanism of microtubule stabilization imparted by the covalent binding of the C-22-C-23 epoxide moiety to tubulin. A taccalonolide (8) with a fluorescein group attached with a linker at C-6 was generated, and biochemical and cell-based assays showed that it bound directly to tubulin and stabilized microtubules. This pharmacological probe has allowed, for the first time, a direct visualization of a taccalonolide binding to microtubules, verifying their cellular binding site. This C-6-modified taccalonolide showed potency comparable to the untagged compound in biochemical experiments; however, its potency was lower in cellular assays, presumably due to decreased cellular permeability. These studies provide a valuable tool to facilitate the further understanding of taccalonolide pharmacology and demonstrate that C-6 is a promising site for a linker to be added to this novel class of microtubule stabilizers for targeted drug delivery.

摘要

塔卡醇内酯是一类微管稳定剂,由于其通过 C-22-C-23 环氧化物部分与微管蛋白的共价结合赋予微管稳定的独特机制,因此可以规避由于临床相关形式的耐药性而产生的药物。生成了一种带有荧光团的带有连接子的 C-6 位连接的塔卡醇内酯(8),生物化学和基于细胞的测定表明它直接与微管蛋白结合并稳定微管。这种药理学探针首次允许直接观察塔卡醇内酯与微管的结合,从而验证了它们的细胞结合部位。与未标记的化合物相比,这种 C-6 修饰的塔卡醇内酯在生化实验中具有相当的效力;然而,在细胞测定中,其效力较低,可能是由于细胞通透性降低所致。这些研究为进一步了解塔卡醇内酯药理学提供了有价值的工具,并表明 C-6 是将该新型微管稳定剂类别的连接子添加到用于靶向药物递送的有希望的位点。

相似文献

2
Taccalonolide microtubule stabilizers.他卡醇内酯类微管稳定剂。
Bioorg Med Chem. 2014 Sep 15;22(18):5091-6. doi: 10.1016/j.bmc.2014.01.012. Epub 2014 Jan 15.
3
Taccalonolide Microtubule Stabilizers.他克林囊泡转运抑制剂
Prog Chem Org Nat Prod. 2020;112:183-206. doi: 10.1007/978-3-030-52966-6_3.

本文引用的文献

3
Strategies and challenges for the next generation of antibody-drug conjugates.下一代抗体药物偶联物的策略与挑战。
Nat Rev Drug Discov. 2017 May;16(5):315-337. doi: 10.1038/nrd.2016.268. Epub 2017 Mar 17.
7
Taxane anticancer agents: a patent perspective.紫杉烷类抗癌药物:专利视角
Expert Opin Ther Pat. 2016;26(1):1-20. doi: 10.1517/13543776.2016.1111872. Epub 2015 Dec 10.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验